CN104334575A - 通道视蛋白-2(Chop2)突变的鉴定及使用方法 - Google Patents

通道视蛋白-2(Chop2)突变的鉴定及使用方法 Download PDF

Info

Publication number
CN104334575A
CN104334575A CN201380022635.5A CN201380022635A CN104334575A CN 104334575 A CN104334575 A CN 104334575A CN 201380022635 A CN201380022635 A CN 201380022635A CN 104334575 A CN104334575 A CN 104334575A
Authority
CN
China
Prior art keywords
molecule
cells
nucleic acid
amino acids
isolated polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380022635.5A
Other languages
English (en)
Chinese (zh)
Inventor
Z-h.潘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wayne State University
Original Assignee
Wayne State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne State University filed Critical Wayne State University
Priority to CN202010025519.0A priority Critical patent/CN111378020A/zh
Publication of CN104334575A publication Critical patent/CN104334575A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/405—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201380022635.5A 2012-03-05 2013-03-05 通道视蛋白-2(Chop2)突变的鉴定及使用方法 Pending CN104334575A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010025519.0A CN111378020A (zh) 2012-03-05 2013-03-05 通道视蛋白-2(Chop2)突变的鉴定及使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261606663P 2012-03-05 2012-03-05
US61/606,663 2012-03-05
PCT/US2013/029171 WO2013134295A1 (en) 2012-03-05 2013-03-05 Identification of channelrhodopsin-2 (chop2) mutations and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010025519.0A Division CN111378020A (zh) 2012-03-05 2013-03-05 通道视蛋白-2(Chop2)突变的鉴定及使用方法

Publications (1)

Publication Number Publication Date
CN104334575A true CN104334575A (zh) 2015-02-04

Family

ID=47892055

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380022635.5A Pending CN104334575A (zh) 2012-03-05 2013-03-05 通道视蛋白-2(Chop2)突变的鉴定及使用方法
CN202010025519.0A Pending CN111378020A (zh) 2012-03-05 2013-03-05 通道视蛋白-2(Chop2)突变的鉴定及使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010025519.0A Pending CN111378020A (zh) 2012-03-05 2013-03-05 通道视蛋白-2(Chop2)突变的鉴定及使用方法

Country Status (16)

Country Link
US (3) US10947281B2 (enExample)
EP (1) EP2822964B1 (enExample)
JP (3) JP6395611B2 (enExample)
KR (1) KR102137717B1 (enExample)
CN (2) CN104334575A (enExample)
AU (4) AU2013230112A1 (enExample)
CA (1) CA2866405A1 (enExample)
DK (1) DK2822964T3 (enExample)
EA (1) EA201491643A1 (enExample)
ES (1) ES2703324T3 (enExample)
HU (1) HUE040487T2 (enExample)
MX (1) MX360085B (enExample)
NZ (1) NZ629843A (enExample)
PL (1) PL2822964T3 (enExample)
PT (1) PT2822964T (enExample)
WO (1) WO2013134295A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109476720A (zh) * 2016-06-03 2019-03-15 马克斯-普朗克科学促进协会 通道视紫红质的突变型光诱导离子通道
CN110023327A (zh) * 2016-08-29 2019-07-16 韦恩州立大学 在具有改善光敏感性的通道视蛋白变体中突变的识别及其使用方法
CN110267972A (zh) * 2016-11-06 2019-09-20 纳秒示波器科技有限公司 由多特征视蛋白进行的用于视力恢复的光学调制以及其其他应用
CN111032068A (zh) * 2017-04-12 2020-04-17 马克斯·普朗克科学促进学会 新的光遗传学工具

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2685900A1 (en) 2006-05-04 2007-11-15 Wayne State University Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
US9453241B2 (en) 2010-05-04 2016-09-27 Wayne State University AAV-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
DK2822964T3 (en) 2012-03-05 2018-12-10 Univ Wayne State IDENTIFICATION OF CHANNEL RHODOPSIN-2- (CHOP2) MUTATIONS AND METHODS OF USE
EP2968476B1 (en) 2013-03-14 2021-05-05 Wayne State University A plasmin for use in enhancing delivery of therapeutic compounds to the eyes or for improving vision
WO2015004565A1 (en) 2013-07-08 2015-01-15 Basf Se Oxime ester photoinitiators
CA3234028A1 (en) 2014-03-11 2015-09-17 Wayne State University A modified mglur6 promoter and methods of use
MX2018013352A (es) 2016-05-03 2019-08-01 Univ Wayne State Metodo para mejorar suministro de genes mediado por virus en el ojo usando inhibidores de proteosoma.
PT3720428T (pt) * 2017-12-04 2023-04-03 Salvat Lab Sa Composição tópica oftálmica compreendendo ácido dobesílico para tratamento de doenças do segmento posterior do olho
JP6567153B1 (ja) * 2018-09-28 2019-08-28 学校法人東北工業大学 対象化合物の特性の予測を行うための方法、コンピュータシステム、プログラム
WO2024226667A2 (en) * 2023-04-24 2024-10-31 Nanoscope Therapeutics Inc. Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4498919A (en) 1983-10-31 1985-02-12 Corning Glass Works Method for making colored photochromic prescription ophthalmic lenses
US6610287B1 (en) 1990-04-16 2003-08-26 The General Hospital Corporation Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5827702A (en) 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
AU7467598A (en) 1997-04-21 1998-11-13 University Of Florida Materials and methods for treatment of retinal diseases
NZ511037A (en) 1998-09-17 2005-02-25 Univ Florida Methods for treatment of degenerative retinal diseases
WO2001083692A2 (en) 2000-04-28 2001-11-08 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
CA2442670A1 (en) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
WO2003016486A2 (en) 2001-08-16 2003-02-27 Sloan Kettering Institute For Cancer Research Bio-synthetic photostimulators and methods of use
DE10216005A1 (de) 2002-04-11 2003-10-30 Max Planck Gesellschaft Verwendung von biologischen Photorezeptoren als direkt lichtgesteuerte Ionenkanäle
WO2004009022A2 (en) 2002-07-18 2004-01-29 The General Hospital Corp. Method for augmenting vision in persons suffering from photoreceptor cell degeneration
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US7427138B2 (en) 2003-11-05 2008-09-23 Neurovision, Inc. Method and apparatus for improving visual perception
EP2465925A1 (en) 2005-07-22 2012-06-20 The Board Of Trustees Of The Leland Light-activated cation channel and uses thereof
CA2685900A1 (en) 2006-05-04 2007-11-15 Wayne State University Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
US9453241B2 (en) 2010-05-04 2016-09-27 Wayne State University AAV-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
US8748578B2 (en) * 2010-09-08 2014-06-10 Max-Planck-Gesellschaft zur Foerderrung der Wissenschaften e.V. Mutant channelrhodopsin 2
DK2822964T3 (en) * 2012-03-05 2018-12-10 Univ Wayne State IDENTIFICATION OF CHANNEL RHODOPSIN-2- (CHOP2) MUTATIONS AND METHODS OF USE
KR101639859B1 (ko) * 2014-03-06 2016-07-14 포항공과대학교 산학협력단 광 자극에 의한 미토콘드리아 활성의 시공간적 가역 조절 방법

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BERNDT A, SCHOENENBERGER P, MATTIS J, TYE KM, DEISSEROTH K, HEGE: ""High-eYciency channelrhodopsins for fast neuronal stimulation at low light levels"", 《PROC NATL ACAD SCI USA》 *
MARTIN L. REIN, JAN M. DEUSSING,: ""The optogenetic (r)evolution"", 《MOL GENET GENOMICS》 *
SONJA KLEINLOGEL.ET AL.: ""Ultra light-sensitive and fast neuronal activation with the Ca2+-permeable channelrhodopsin CatCh"", 《NATURE NEUROSCIENCE》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109476720A (zh) * 2016-06-03 2019-03-15 马克斯-普朗克科学促进协会 通道视紫红质的突变型光诱导离子通道
CN110023327A (zh) * 2016-08-29 2019-07-16 韦恩州立大学 在具有改善光敏感性的通道视蛋白变体中突变的识别及其使用方法
CN110023327B (zh) * 2016-08-29 2024-02-27 韦恩州立大学 在具有改善光敏感性的通道视蛋白变体中突变的识别及其使用方法
CN110267972A (zh) * 2016-11-06 2019-09-20 纳秒示波器科技有限公司 由多特征视蛋白进行的用于视力恢复的光学调制以及其其他应用
CN111032068A (zh) * 2017-04-12 2020-04-17 马克斯·普朗克科学促进学会 新的光遗传学工具

Also Published As

Publication number Publication date
DK2822964T3 (en) 2018-12-10
AU2021245195A1 (en) 2021-11-04
PL2822964T3 (pl) 2019-05-31
HK1205744A1 (en) 2015-12-24
MX2014010664A (es) 2015-03-06
JP6395611B2 (ja) 2018-09-26
US20220033449A1 (en) 2022-02-03
CA2866405A1 (en) 2013-09-12
PT2822964T (pt) 2018-11-29
US10947281B2 (en) 2021-03-16
KR102137717B1 (ko) 2020-07-27
MX360085B (es) 2018-10-10
ES2703324T3 (es) 2019-03-08
WO2013134295A1 (en) 2013-09-12
CN111378020A (zh) 2020-07-07
JP2019193656A (ja) 2019-11-07
AU2021245195B2 (en) 2023-09-28
NZ727041A (en) 2022-01-28
KR20140132401A (ko) 2014-11-17
AU2017239601B2 (en) 2019-05-16
EA201491643A1 (ru) 2015-02-27
HUE040487T2 (hu) 2019-03-28
EP2822964A1 (en) 2015-01-14
US20250066431A1 (en) 2025-02-27
AU2017239601A1 (en) 2017-10-26
US20150044181A1 (en) 2015-02-12
EP2822964B1 (en) 2018-08-22
AU2019216638A1 (en) 2019-09-05
JP2018134098A (ja) 2018-08-30
JP2015510759A (ja) 2015-04-13
AU2019216638B2 (en) 2021-07-08
NZ629843A (en) 2017-03-31
AU2013230112A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
US20250066431A1 (en) Identification of channelrhodopsin-2 (chr2) mutations and methods of use
ES2742499T5 (es) Tratamiento de la degeneración retinal mediante terapia génica
ES2538468T3 (es) Vectores para la administración de proteínas sensibles a la luz y métodos para su utilización
US20240165198A1 (en) Optogenetic visual restoration using chrimson
EP4132961A1 (en) G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd)
JP6779546B2 (ja) 視力回復のための多特性オプシンによる光遺伝学的調節及びその別の用途
HK1205744B (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
EA043449B1 (ru) ИДЕНТИФИКАЦИЯ МУТАЦИЙ КАНАЛ-ОПСИНА-2 (Chop2) И СПОСОБЫ ПРИМЕНЕНИЯ
NZ727041B2 (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150204

RJ01 Rejection of invention patent application after publication